Georges Gemayel, Ph.D., Joins Supernus Board of Directors
March 23 2015 - 5:00PM
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system (CNS)
diseases, today announced that Georges Gemayel, Ph.D., a veteran
executive with extensive experience in the pharmaceutical industry,
will join the company's board of directors.
"Georges is a leader who has an excellent track record of
commercial and product development success helping pharmaceutical
companies achieve and sustain growth," said Jack Khattar, chief
executive officer of Supernus Pharmaceuticals. "His experience with
growth companies will be especially valuable to Supernus as we
build upon the success of our marketed products and advance our
pipeline towards commercialization."
Dr. Gemayel has over 25 years of experience in the
pharmaceutical industry, including management and executive
positions in the U.S., Europe and the Middle East. Dr. Gemayel
currently serves on the board of directors of Raptor
Pharmaceuticals, a publicly-traded company, and is the chairman of
the boards of OxThera, EpiTherapeutics and Orphazyme ApS.
From 2008 to 2009, Dr. Gemayel was president and chief executive
officer of Altus Pharmaceuticals, a publicly-traded pharmaceutical
company. From 2003 to 2008, he was executive vice president at
Genzyme Corporation where he was responsible for the company's
global therapeutics, transplant, renal and biosurgery businesses.
From 1998 to 2003, he held progressively senior roles at Hoffmann
La-Roche and Roche Labs, most recently as vice president, National
Specialty Care, responsible for its U.S. business for dermatology,
oncology, transplantation, hepatitis and HIV.
"Supernus achieved great success in developing its CNS portfolio
and becoming profitable only one year after launching Oxtellar XR
and Trokendi XR," said Georges Gemayel, Ph.D. "I look forward to
working closely with Supernus' Board and Management to maximize the
potential of its commercial products and progress its innovative
pipeline in psychiatry."
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
has two marketed products for epilepsy, Oxtellar XR®
(extended-release oxcarbazepine) and Trokendi XR® (extended-release
topiramate). The Company is also developing several product
candidates to address large market opportunities in psychiatry.
These product candidates include SPN-810 for the treatment of
impulsive aggression in patients with ADHD in conjunction with
standard ADHD treatment and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
301-838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024